Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Entrada Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.78) Estimate, Sales $19.57M Beat $12.32M Estimate

Author: Benzinga Newsdesk | November 05, 2024 07:26am
Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.78) by 55.13 percent. The company reported quarterly sales of $19.57 million which beat the analyst consensus estimate of $12.32 million by 58.83 percent. This is a 55.25 percent decrease over sales of $43.73 million the same period last year.

Posted In: TRDA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist